Brind.

BioMarin Pharmaceutical's stock fell while the S&P 500 climbed on August 20, 2025.

2 reports, 2 independent Updated Aug 20

Gone quiet Reached 2 outlets in its first 24 hours

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

BioMarin Pharmaceutical's stock fell while the S&P 500 climbed on August 20, 2025.

Who's involved

What this event is mainly about

BioMarin Pharmaceutical

Keep exploring

The entities involved

BioMarin Pharmaceutical
American company
- Investors are comparing the financial performance metrics of BioMarin Pharmaceutical and Metagenomi.Sun 20:41

Related events

Applied DNA Sciences and BioMarin Pharmaceutical are identified as competing companies within the healthcare market.Sep 3

Coverage

Newest first; wire copies grouped

Aug 20StockStory2 Reasons to Watch BMRN and 1 to Stay Cautious Over the past six months, BioMarin Pharmaceutical’s stock price fell to $57. Shareholders have lost 17.1% of their capital, which is disappointing consi
Aug 5ZacksBioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $1.44 per share, beating the Zacks Consensus Estimate of $